Alebund Pharmaceuticals HK$1.28 billion IPO
We advised Alebund Pharmaceuticals on its IPO and HKEX listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Talawar Therapeutics $225 million PIPE financing and de-SPAC transaction
We advised the placement agents on the transaction
NeoGenomics $316.25 million convertible senior notes offering
We advised the initial purchasers on the offering
SOPHiA GENETICS $57.5 million follow-on offering
We advised SOPHiA GENETICS on the offering
PTC Therapeutics $550 million convertible senior notes offering
We advised the initial purchasers on the offering
IDEAYA Biosciences $345 million equity offering
We advised the joint book-running managers and underwriters on the offering
Novanta $300 million private placement
We advised the placement agents on the transaction
Inventiva $120 million underwritten offering
We advised the underwriters on the offering
Sumitomo Pharma ¥102.1 billion stock offering
We advised the joint lead managers and joint bookrunners on the offering
CARsgen HK$470 million placement of shares and top-up subscription
We advised CARsgen on the placement and top-up subscription